GLSI on XNAS, Health Care, Greenwich LifeSciences, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 136% in 12 months but down 30% in six months, while 11% of shares are sold short.
BadCash of $5.9M sits against a $24.6M net loss over 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $5.8M.
31 Dec 2021RevenueNet incomeNet losstallest bar $9.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$5.8M
30 Jun 2026
–
-$3.9M
31 Mar 2026
–
-$5.7M
31 Dec 2025
–
-$9.2M
30 Sep 2025
–
-$4.2M
30 Jun 2025
–
-$4.0M
31 Mar 2025
–
-$3.3M
31 Dec 2024
–
-$8.0M
30 Sep 2024
–
-$2.7M
30 Jun 2024
–
-$2.6M
31 Mar 2024
–
-$2.5M
31 Dec 2023
–
-$2.7M
30 Sep 2023
–
-$2.4M
30 Jun 2023
–
-$1.6M
31 Mar 2023
–
-$2.1M
31 Dec 2022
–
-$2.8M
30 Sep 2022
–
-$2.3M
30 Jun 2022
–
-$746K
31 Mar 2022
–
-$2.0M
31 Dec 2021
–
-$2.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$24.6M
-$18.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.73
-$1.37
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$5.9M
$3.8M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$5.9M (net cash)
-$3.8M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-8.6%
53 13F filers vs 58
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
12%
1.7M shares held by 13F filers (30 Sep 2026) of 14.7M outstanding (6 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
11%
1.6M shares sold short (30 Oct 2026) of 14.7M outstanding (6 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
12.5
1.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+1.7%
1.6M shares sold short in the report before, 1.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
78%
78% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
30
30 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
15×
30 articles in the last 7 days; its usual week has 2.
Price $19.25 on 20 Nov 2026, +136% over 12 months (12-month range $7.85 to $33.56)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $437K in the last 12 months (the 12 months before: $515K).Institutional holders (13F filers). 53 13F filers reported holding it in the latest 13F quarter, +6.0% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short sale volume on FINRA-reported off-exchange venues (TRFs + ADF), shares per day at 148K (20 Nov 2026), 4.0× its normal reading; higher than 97% of its own history.
had 501K shares sold short in the 15 Oct 2024 report, 2.7× the same report last year.
Same report last year: 184K; its normal report is 181K.
See the evidence
This period
501K (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
34K
How far from its usual level
+6.3
Same report last year
184K
History used
1,476 days
the 15 Oct 2024 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 505K shares sold short in the 13 Sep 2024 report, 2.6× the same report last year.
Same report last year: 195K; its normal report is 181K.
See the evidence
This period
505K (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
23K
How far from its usual level
+6.5
Same report last year
195K
History used
1,444 days
the 13 Sep 2024 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 125 entries; narrow the window or the kind of data to see older ones.
Not listed: 50 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001799788
Ticker
GLSI
Domain
greenwichlifesciences.com
Hq location
TX|STAFFORD|77477 (1 unverified)
Name
Greenwich LifeSciences, Inc.
SEC Form 13F institutional holdings225 data points30 Sep 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)69 records1 Jun 2020 to 16 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)324 data points31 Dec 2018 to 6 Nov 2026
SEC Form 4 insider transactions118 records, 416 data points29 Sep 2020 to 30 Jul 2026
FINRA short interest (twice monthly)437 data points30 Sep 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3094 data points25 Sep 2020 to 20 Nov 2026